143 related articles for article (PubMed ID: 7488437)
1. Ondansetron for the control of dacarbazine-induced emesis.
Campora E; Chiara S; Aschele C
Eur J Cancer; 1995 Sep; 31A(10):1720-1. PubMed ID: 7488437
[No Abstract] [Full Text] [Related]
2. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting.
Fedele P; Spina M; Valentini M; Collini D; Lucia C; Manicone M; Tirelli U
Cancer; 1995 Aug; 76(3):535-6. PubMed ID: 8625142
[No Abstract] [Full Text] [Related]
3. Progress in preventing chemotherapy-induced nausea and vomiting.
Markman M
Cleve Clin J Med; 2002 Aug; 69(8):609-10, 612, 615-7. PubMed ID: 12184469
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
Legha SS; Hodges C; Ring S
Cancer; 1992 Oct; 70(7):2018-20. PubMed ID: 1388090
[TBL] [Abstract][Full Text] [Related]
5. Prevention of delayed emesis caused by chemotherapy.
Harmon D; O'Brien B
N Engl J Med; 2000 Sep; 343(12):889; author reply 889-90. PubMed ID: 11001695
[No Abstract] [Full Text] [Related]
6. CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.
Wilbur MB; Birrer MJ; Spriggs DR
N Engl J Med; 2016 Jul; 375(2):177-9. PubMed ID: 27410928
[No Abstract] [Full Text] [Related]
7. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
Ossi M; Anderson E; Freeman A
Oncology; 1996 Jun; 53 Suppl 1():78-85. PubMed ID: 8692556
[TBL] [Abstract][Full Text] [Related]
8. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Cocquyt V; Van Belle S; Reinhardt RR; Decramer ML; O'Brien M; Schellens JH; Borms M; Verbeke L; Van Aelst F; De Smet M; Carides AD; Eldridge K; Gertz BJ
Eur J Cancer; 2001 May; 37(7):835-42. PubMed ID: 11313170
[TBL] [Abstract][Full Text] [Related]
9. Cipropride in preventing nausea and vomiting induced by severely emetic cytostatic agents.
Serrou B; Cupissol D; Rosenfeld C; Metz R; Coquelin JP; Sauvanet JP
J Int Med Res; 1981; 9(5):390-1. PubMed ID: 7197651
[No Abstract] [Full Text] [Related]
10. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
Italian Group for Antiemetic Research
N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073
[TBL] [Abstract][Full Text] [Related]
11. [ESMO 2004. Nausea and vomiting caused by chemotherapy: improving the treatment].
Longo F; Mansueto G
Tumori; 2005; 91(1):suppl 36-48. PubMed ID: 15850022
[No Abstract] [Full Text] [Related]
12. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.
Farley PA; Dempsey CL; Shillington AA; Kulis-Robitaille C; Colgan K; Bernstein G
Am J Health Syst Pharm; 1997 Nov; 54(21):2478-82. PubMed ID: 9359954
[TBL] [Abstract][Full Text] [Related]
13. Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy.
Sagar SM; Bayliss MA; Chong SL; Retsas S
Clin Oncol (R Coll Radiol); 1991 May; 3(3):183. PubMed ID: 1829958
[No Abstract] [Full Text] [Related]
14. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy.
du Bois A; McKenna CJ; Andersson H; Lahousen M; Kitchener H; Pinter T; Capstick V; Wilkinson JR
Oncology; 1997; 54(1):7-14. PubMed ID: 8978585
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
16. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
[TBL] [Abstract][Full Text] [Related]
17. Fighting nausea in the '90s: more and better anti-emetics can help.
Saphir A
J Natl Cancer Inst; 1997 Sep; 89(17):1252-5. PubMed ID: 9293911
[No Abstract] [Full Text] [Related]
18. [Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
Gershanovich ML; Beresneva IA; Makhnova EV
Vopr Onkol; 2003; 49(4):505-9. PubMed ID: 14569947
[TBL] [Abstract][Full Text] [Related]
19. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
20. Review of experience with ondansetron and granisetron.
Aapro MS
Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
